Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia

• প্রধান লেখক: Luma Al-Ali (লেখক), Raad J. Al-Ani (লেখক), Maysaa M. Saleh (লেখক), Alaa M. Hammad (লেখক), Duaa A. Abuarqoub (লেখক), Bashaer Abu-Irmaileh (লেখক), Abdallah Y. Naser (লেখক), Manal M. Najdawi (লেখক), Manal M. Abbas (লেখক), Jamal Alyoussef Alkrad (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2024-02-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Background: The use of tyrosine kinase inhibitors (TKIs) as a treatment for chronic myeloid leukemia (CML) has improved the natural history of the disease and increased the duration of survival. Tyrosine kinase inhibitors represent the success of target therapies that work on molecular targets, alth...